



# Endocrine and Metabolic Agents X-Linked Hypophosphatemia Agents (Crysvita)

## WA.PHAR.107 Endocrine and Metabolic Agents X-Linked Hypophosphatemia Agents (Crysvita)

Effective Date: January 1, 2019

### Background:

Burosumab-twza (Crysvita®) is a fibroblast growth factor 23 (FGF23) blocking antibody managed and paid by the Health Care Authority for Medicaid members.

***All requests for authorization or payment must be referred to the Health Care Authority.***

### Coding:

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPSC Code	Description
J0584	INJECTION BUROSUMAB-TWZA 1 MG

### History

Date	Action and Summary of Changes
12/21/2020	<ul style="list-style-type: none"><li>New Policy Created</li></ul>